Download PDF
Osteosynthesis and Trauma Care 2003; 11(1): 38-40
DOI: 10.1055/s-2003-40119
Case Report

© Georg Thieme Verlag Stuttgart · New York

Neutropenia Associated with Piperacillin/Tazobactam (Zosyn) in the Treatment of Orthopedic Injuries: A Case Report

C. J. Wallach1 , N. Rao 2 , G. S. Gruen3
  • 1Department of Orthopedic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
  • 2University of Pittsburgh Medical Center, Shadyside Hospital, and University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
  • 3Division of Orthopedic Traumatology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Further Information

Publication History

Publication Date:
20 June 2003 (online)

    Permissions and Reprints

Abstract

Neutropenia is a potentially fatal complication of intravenous Piperacillin/Tazobactam therapy not previously reported in the orthopedic literature. We report five cases that presented to the orthopedic service in a two-month period.

Key words

Neutropenia - Piperacillin/Tazobactam - Orthopedics - Open Fractures

References

  • 1 Lang R, Lishner M, Ravid M. Adverse reactions to prolonged treatment with high doses of carbenicillin and ureidopenicillins.  Rev Infect Dis. 1991;  13 68-72
    PubMedGoogle Scholar
  • 2 Gerber L, Wing E J. Life-threatening neutropenia secondary to piperacillin/tazobactam therapy.  Clin Infect Dis. 1995;  21 1047-1048
    PubMedGoogle Scholar
  • 3 Mallon P, Murphy P, Elborn S. Fever associated with intravenous antibiotics in adults with cystic fibrosis.  Lancet. 1997;  350 1676-1677
    PubMedGoogle Scholar
  • 4 Reichardt P, Handrick W, Linke A, Schille R, Kiess W. Leukocytopenia, thrombocytopenia and fever related to piperacillin/tazobactam treatment - a retrospective analysis in 38 children with cystic fibrosis.  Infection. 1999;  27 355-356
    CrossrefPubMedGoogle Scholar
  • 5 Toyonaga Y, Ishihara T, Tezuka T, Nakamura H. [Pharmacokinetic and clinical evaluation of tazobactam/piperacillin in the pediatric field].  Jpn J Antibiot. 1998;  51 325-345
    PubMedGoogle Scholar
  • 6 Patzakis M J, Wilkins J. Factors influencing infection rate in open fracture wounds.  Clin Orthop. 1989;  36-40
    PubMedGoogle Scholar
  • 7 Wilkins J, Patzakis M. Choice and duration of antibiotics in open fractures.  Orthop Clin North Am. 1991;  22 433-437
    PubMedGoogle Scholar
  • 8 Archer G, Polk R. Treatment and prophylaxis of bacterial infections. In al. FAe (ed): Harrison’s Principles of Internal Medicine (ed 14), McGraw-Hill 1998; pp 856-868
    Google Scholar
  • 9 Muller T HT. Efficacy and safety of Tazobactam/Piperacillin in the treatment of bone and joint infections. Paper presented at the The 4th Biennial Conference on Chemotherapy of Infectious Diseases and Malignancies, Czechoslovakia 1992
    Google Scholar
  • 10 Incavo S J. Penetration of piperacillin-tazobactam into cancellous and cortical bone tissues.  Antimicrobial Agents & Chemotherapy. 1994;  38 905-907
    PubMedGoogle Scholar

Gary S. Gruen MD 

Department of Orthopedic Surgery · University of Pittsburgh Medical Center

3471 Fifth Avenue, Suite 1010

Pittsburgh, PA 15213

USA

Phone: +1/4 12/6 05 32 11

Fax: +1/4 12/6 87 37 24

Email: ggruen@uoi.upmc.edu

      >